Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03851601 · ClinicalTrials.gov registry record
Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 6
- Enrollment target
NCT03851601: Completed study, sponsored by Henry Ford Health System.
NCT03851601 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03851601 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Extracorporeal Photopheresis (ECP) has been used as one of the treatments for graft versus host disease (GVHD). Responses were observed in skin, liver, GI tract, mouth, eye and lung. ECP does not cause immune suppression and therefore less risk of infection or relapse of malignancy. However, the exact mechanism of action of this expensive procedure is not fully understood and no predictors of response to ECP are known so far. This reflects the need for a better understanding of GVHD and its response to ECP. Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using flow cytometer
Primary Outcome
investigate the effect of ECP on Tregs/TH17 ratio using flow-cytometry in patients with GVHD who receive treatment with ECP
Interventions
- OTHER blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-08-26 |
| Est. Completion | 2023-06-30 |
What the finished NCT03851601 record still lists
NCT03851601 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which blood samples is the first listed.
NCT03851601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03851601 about?
NCT03851601 is a clinical study titled "Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis". Extracorporeal Photopheresis (ECP) has been used as one of the treatments for graft versus host disease (GVHD). Responses were observed in skin, liver, GI tract, mouth, eye and lung. ECP does not cause immune suppression and therefore less risk of infection or relapse of malignancy. However, the exa...
What is the current status of trial NCT03851601?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2014-08-26. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03851601?
The interventions under investigation include: blood samples (OTHER).
Who is sponsoring clinical trial NCT03851601?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI